Bouhanick B
Service de Médecine B, Centre Hospitalier Universitaire, Angers, France.
Therapie. 1996 Jan-Feb;51(1):41-7.
To test if calcium antagonists and converting enzyme inhibitors can act similarly on urinary albumin excretion of type 2, non-insulin-dependent diabetic subjects with hypertension, a 24 week, double-blind, randomized, parallel multicentre study was performed in 111 such patients allocated to nicardipine 50 mg slow release form (n = 57) or to captopril 25 mg (n = 54) twice daily. The efficacy of both drugs was similar on urinary albumin excretion (Westlake test p = 0.19). However, blood pressure was lower on nicardipine than on captopril (p < 0.05), and the antialbuminuric effect of nicardipine was related to its hypotensive effect, while this was not the case for captopril. The two drugs were tolerated equally. Thus, nicardipine and captopril for 24 weeks can be equally effective on urinary albumin excretion of type 2, non-insulin-dependent diabetic subjects with hypertension, but the mechanisms of their anti-albuminuric effects may be different.
为了测试钙拮抗剂和转换酶抑制剂对伴有高血压的2型非胰岛素依赖型糖尿病患者尿白蛋白排泄的作用是否相似，对111例此类患者进行了一项为期24周的双盲、随机、平行多中心研究，这些患者被分配至每日两次服用50毫克缓释尼卡地平组（n = 57）或25毫克卡托普利组（n = 54）。两种药物对尿白蛋白排泄的疗效相似（韦斯特莱克检验p = 0.19）。然而，尼卡地平组的血压低于卡托普利组（p < 0.05），且尼卡地平的抗蛋白尿作用与其降压作用有关，而卡托普利并非如此。两种药物的耐受性相同。因此，尼卡地平和卡托普利治疗24周对伴有高血压的2型非胰岛素依赖型糖尿病患者的尿白蛋白排泄可能同样有效，但它们的抗蛋白尿作用机制可能不同。
